| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | ALKS Alkermes Plc. | Nichols Christian Todd48 | SVP, Chief Commercial Officer | Sell | 6,667 | $31.52 | $210,143.41 | -3.7% | -8.4% | +41.1% | |
| Jun 10, 2025 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 30,204 | $30.59 | $923,827.13 | -13.4% | +27.6% | - | |
| Jun 10, 2025 | ORGO Organogenesis Holdings Inc. | Nussdorf Glenn H70 | Director, 10% Owner | Sell | 22,776 | $3.55 | $80,802.79 | -3.2% | +37.5% | -28.8% | |
| Jun 9, 2025 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 12,000 | $325.37 | $3,904,496.06 | -15.5% | +20.2% | +68.4% | |
| Jun 9, 2025 | COLL Collegium Pharmaceutical, Inc | Freund John Gordon79 | Director | Sell | 6,601 | $30.62 | $202,149.02 | -8.5% | +24.0% | +9.7% | |
| Jun 9, 2025 | AYTU Aytu Biopharma, Inc | Disbrow Joshua R.57 | Chief Executive Officer | Buy | 66,666 | $1.50 | $99,999.00 | +77.0% | +7.6% | +9.0% | |
| Jun 9, 2025 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.54 | CFO And Treasurer | Sell | 39,773 | $83.00 | $3,301,295.84 | -10.8% | -35.6% | +20.1% | |
| Jun 9, 2025 | AKBA Akebia Therapeutics, Inc. | Malabre Richard C69 | SVP, Chief Accounting Officer | Sell | 15,000 | $4.01 | $60,150.00 | -5.3% | -18.3% | -76.0% | |
| Jun 9, 2025 | AYTU Aytu Biopharma, Inc | Disbrow Jarrett | Chief Business Officer | Buy | 16,666 | $1.50 | $24,999.00 | +130.2% | +7.6% | +9.0% | |
| Jun 9, 2025 | LNTH Lantheus Holdings, Inc. | McHugh Julie55 | Director | Sell | 5,192 | $81.62 | $423,771.04 | -16.7% | -35.6% | +20.1% | |
| Jun 9, 2025 | EOLS Evolus, Inc. | White Albert G III48 | Director | Buy | 20,000 | $9.45 | $189,000.00 | +65.8% | -21.1% | -30.6% | |
| Jun 9, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 86,500 | $0.41 | $35,160.92 | +0.1% | - | - | |
| Jun 6, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 5,100 | $56.00 | $285,600.00 | -1.0% | -14.6% | -53.5% | |
| Jun 6, 2025 | ORGO Organogenesis Holdings Inc. | Freedman Lori | Chief Admin. And Legal Officer | Buy | 252,264 | $2.88 | $725,290.02 | +11.9% | +66.0% | -20.1% | |
| Jun 5, 2025 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel55 | See Remarks | Sell | 6,000 | $79.65 | $477,900.00 | -6.1% | -31.3% | +25.7% | |
| Jun 5, 2025 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | President | Sell | 6,599 | $79.65 | $525,610.35 | -5.6% | -31.3% | +25.7% | |
| Jun 5, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 26,000 | $0.41 | $10,530.00 | - | - | - | |
| Jun 5, 2025 | ETON Eton Pharmaceuticals, Inc. | Brynjelsen Sean | President &CEO | Sell | 210,000 | $17.11 | $3,592,611.00 | -1.4% | +1.2% | +68.9% | |
| Jun 4, 2025 | VRNO Verano Holdings Corp. | Weiss Darren Henry | President | Sell | 24,901 | $0.60 | $14,940.60 | -3.6% | - | - | |
| Jun 4, 2025 | VRNO Verano Holdings Corp. | Miles Aaron Nathaniel | Chief Investment Officer | Sell | 5,018 | $0.60 | $3,011.30 | -1.8% | - | - | |
| Jun 4, 2025 | VRNO Verano Holdings Corp. | Kalesnik Laura Marie | See Remarks | Sell | 5,850 | $0.60 | $3,510.00 | -2.1% | - | - | |
| Jun 4, 2025 | AKBA Akebia Therapeutics, Inc. | Malabre Richard C69 | SVP, Chief Accounting Officer | Sell | 13,334 | $3.53 | $47,069.02 | -4.8% | -14.6% | -73.4% | |
| Jun 4, 2025 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 6,656 | $16.97 | $112,952.32 | -2.9% | +62.4% | +255.3% | |
| Jun 4, 2025 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 7,597 | $16.97 | $128,921.09 | -2.7% | +62.4% | +255.3% | |
| Jun 4, 2025 | PCRX Pacira Biosciences, Inc. | Riker Lauren76 | Senior Vice President, Finance | Sell | 5,578 | $26.21 | $146,208.16 | -8.6% | +0.9% | -16.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.